Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29106639 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL29102850 | 0.84 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL4123685 | 0.83 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL9569532 | 0.82 | ALDH1A1 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL23670092 | 0.82 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL18767010 | 0.81 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL16840382 | 0.81 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL22468783 | 0.81 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL27521834 | 0.81 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL641418 | 0.80 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12209102-B2 | Heterocyclic compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2025012195-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| EP-4489738-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4438123-A2 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240270736-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-08-15 | — | — | US | disclosed |
| US-12054496-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2008053496-A2 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF CIS (-)-LAMIVUDINE | LUPIN LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
| WO-2007120528-A2 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-0532423-A1 | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4959391-A | LIPOXYGENASE INHIBITORS, LEUKOTRIENE DISEASES | GRUENENTHAL GMBH (DE) | 1990-09-25 | — | — | US | disclosed |
| WO-1990009998-A1 | NOVEL ACYCLIC NUCLEOSIDE ANALOGUES, PROCESS FOR THEIR PRODUCTION AND USE OF THESE COMPOUNDS AS ANTI-VIRAL DRUGS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-09-07 | — | — | WO | disclosed |
| EP-0202529-B1 | PHENOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THESE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Grünenthal GmbH (DE) | 1989-12-13 | — | — | EP | disclosed |
| US-4760087-A | 5-lipoxygenase inhibitor | GRUENENTHAL GMBH (DE) | 1988-07-26 | — | — | US | disclosed |
| EP-0202529-A2 | Phenol derivatives, pharmaceutical compositions containing them and processes for the preparation of these compounds and pharmaceutical compositions | Grünenthal GmbH (DE) | 1986-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | SMYD2 2565/4885CYP3A4 3728/4885HTT 430/4885 |
| US-12054496-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DHFR | SMYD2 1069/4885CYP3A4 132/4885HTT 3720/4885 |
| US-12209102-B2 | Heterocyclic compounds and uses thereof | TP53, HRAS, KRAS | SMYD2 2565/4885CYP3A4 3728/4885HTT 430/4885 |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | VCAM1, AOC3, AOC2 | SMYD2 2011/4885CYP3A4 3872/4885HTT 2579/4885 |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | SMYD2 2565/4885CYP3A4 3728/4885HTT 430/4885 |
| US-20240270736-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | TP53, HRAS, KRAS | SMYD2 3292/4885CYP3A4 4030/4885HTT 401/4885 |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | SMYD2 1239/4885CYP3A4 130/4885HTT 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.